Biotech company Leyden Labs receives €30 million for its anti-virus spray
The biotech company Leyden Labs from Leiden has received an investment of €30 million for their new medicine, the PanFlu nasal spray. The nasal spray offers protection against flu viruses by leaving antibodies in the nose. This ensures that the virus particles are no longer harmful before they enter the body.
Seasonal flu declines
Invest-NL and the European Innovation Council (EIC) Fund provided funding to advance the nasal spray's development and commercialization. The nasal spray offers protection to vulnerable groups, including the elderly and people with weakened immune systems. This reduces the burden of seasonal flu and ensures that Europe is better prepared for future pandemics.
Immune system
The nasal spray is effective against various types of flu, including new variants, because the antibodies target parts of the virus that hardly change. What also makes the nasal spray unique is that the protection does not depend on an active immune system, which means that the spray also protects people who normally respond less well to vaccines.
Leyden Labs is thus taking an important step in improving healthcare focused on virus control.
